MEDICALSYSTEM(SZ:300439) Xin Lang Cai Jing·2025-11-24 06:11Core Viewpoint - Meikang Bio's stock price has shown fluctuations, with a recent increase of 2.07% but a year-to-date increase of only 0.53%, indicating potential volatility in the market [1]. Financial Performance - For the period from January to September 2025, Meikang Bio reported a revenue of 1.136 billion yuan, a year-on-year decrease of 19.27% [2]. - The net profit attributable to the parent company was 60.53 million yuan, reflecting a significant year-on-year decline of 73.02% [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Meikang Bio was 23,900, a decrease of 6.95% from the previous period [2]. - The average number of circulating shares per shareholder increased by 7.47% to 12,234 shares [2]. Market Activity - On November 24, Meikang Bio's stock was trading at 10.37 yuan per share, with a total market capitalization of 3.985 billion yuan [1]. - The stock experienced a net outflow of main funds amounting to 2.9142 million yuan, with large orders accounting for 6.43% of purchases and 16.54% of sales [1]. Business Overview - Meikang Bio, established on July 22, 2003, and listed on April 22, 2015, specializes in the research, production, and sales of in vitro diagnostic products, as well as providing third-party medical diagnostic services [1]. - The revenue composition includes 67.88% from in vitro diagnostic reagents, 20.40% from medical diagnostic services, 10.48% from in vitro diagnostic instruments, and 1.24% from other sources [1]. Dividend Information - Since its A-share listing, Meikang Bio has distributed a total of 388 million yuan in dividends, with 143 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the fifth largest circulating shareholder was the Medical Device ETF (159883), which holds 1.4234 million shares as a new shareholder [3].